ViewRay, Inc. announced that Chindex Medical Limited (Chindex), through its subsidiary, has ordered 10 MRIdian® MR-Guided Therapy Systems. Chindex has been ViewRay's distribution partner since 2019. MRIdian received regulatory approval in September 2022 from the National Medical Products Administration (NMPA), allowing for its sale and utilization throughout China. This approval expands MRIdian's global reach and offers cancer patients anew radiation therapy option, MRIdian Stereotactic MRI-Guided Adaptive Radiotherapy (SMART).

The MRIdian system provides oncologists outstanding anatomical visualization through diagnostic-quality MR images and the ability to adapt a radiation therapy plan to the targeted cancer with the patient on the table. This combination allows physicians to define tight treatment margins to avoid unnecessary radiation exposure of vulnerable organs-at-risk and healthy tissue and allows the delivery of ablative radiation doses in five or fewer treatment sessions, without relying on implanted markers. By providing real-time continuous tracking of the target and organs at risk, MRIdian enables automatic gating of the radiation beam if the target moves outside the user-defined margins.

This allows for the delivery of the prescribed dose to the target while sparing surrounding healthy tissue and critical structures, which results in minimizing toxicities typically associated with conventional radiation therapy.